Please login to the form below

Not currently logged in
Email:
Password:

Vertex Pharma

This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.

Vertex faces rejection of its CF medicines in Scotland

Vertex faces rejection of its CF medicines in Scotland

The SMC’s decision follows a history of rejections of Vertex’s CF drugs, with NHS England labelling the American pharma company an “extreme outlier” in its pricing and behaviour. ... The CF Buyers’ Club has sourced a generic copy of Orkambi

Latest news

  • Vertex files cystic fibrosis triple therapy with FDA Vertex files cystic fibrosis triple therapy with FDA

    If approved, the triple therapy could transform treatment of the disease – and Vertex’s fortunes with it. ... approved Vertex medicine, as well as toward providing significantly enhanced benefits to patients with two F508del mutations.

  • Vertex eyes Duchenne market with Exonics, CRISPR deals Vertex eyes Duchenne market with Exonics, CRISPR deals

    Biotech has gene-editing expertise. Vertex Pharma has agreed a pair of deals to build a position in gene-editing therapeutics for diseases like Duchenne muscular dystrophy. ... Vertex's track record in bringing genetic therapies to market stands in its

  • Vertex makes choice for all-important CF triple therapy Vertex makes choice for all-important CF triple therapy

    Now Vertex is on track to file its triple combination, with approval expected in the first half of 2020. ... committee. Vertex plans to file the combination with the FDA in the third quarter of 2019, with submission to the European Medicines Agency to

  • Is Orkambi deal close? Vertex meets again today with NHS England Is Orkambi deal close? Vertex meets again today with NHS England

    This was followed by a meeting between Vertex CEO Jeff Leiden and UK health secretary Matt Hancock, who described the talks as ‘constructive’. ... This in turn led to the pharma company restarting talks with NICE and NHS England, with a second

  • Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

    Vertex CEO Jeff Leiden. The deadlock between pharma company Vertex and NHS England over cystic fibrosis drug Orkambi was played out today in a parliamentary hearing in London, with the ... Both sides have thrown accusations via public statements and the

More from news
Approximately 6 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    This includes overriding pharma patents – something the group is advocating in relation to three drugs – Vertex’s cystic fibrosis treatment Orkambi, Pfizer’s breast cancer treatment Ibrance and Roche’s breast ... Meticulous preparations. The

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.

  • The Orkambi blame game The Orkambi blame game

    The deadlock between pharma company Vertex and NHS England over cystic fibrosis drug Orkambi was played out in a parliamentary hearing in London on 7 March, when the company’s CEO ... NHS England accusing Vertex of being an“extreme outlier” and

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease

  • The challenges of making genomics a reality for patients today, not tomorrow The challenges of making genomics a reality for patients today, not tomorrow

    and higher risk science. The report singles out Vertex among a handful of successful biotech companies with highly innovative products. ... Dr Gillian Burgess is site head of UK Research and Vice President at Vertex.

More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Vertex poaches new finance chief from Ironwood Pharmaceuticals Vertex poaches new finance chief from Ironwood Pharmaceuticals

    Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Tom has the ideal blend of financial acumen, leadership skills,

  • BMS appoints three independent directors BMS appoints three independent directors

    Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Cogora

    Nutricia. Orion Pharma. Orphan Europe. Pfizer. Portola. Prostate Cancer UK. Primary Care Respiratory Society. ... Reckitt Benckiser. Stallergenes. Sun Pharma. Takeda. ThermoFisher Scientific. Vertex.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics